Search Results - "Harold, Nancy"

Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer by Van Waes, Carter, M.D., Ph.D, Allen, Clint T., M.D, Citrin, Deborah, M.D, Gius, David, M.D., Ph.D, Colevas, A. Dimetrios, M.D, Harold, Nancy A., R.N, Rudy, Susan, R.N., C.R.N.P, Nottingham, Liesl, M.D, Muir, Christine, R.N, Chen, Zhong, Ph.D, Singh, Anurag K., M.D, Dancey, Janet, M.D, Morris, John C., M.D

“…Purpose Epidermal growth factor receptor (EGFR) overexpression in head-and-neck squamous cell carcinoma (HNSCC) stimulates tumor cell proliferation, inhibits…”
Get full text

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer by Leonard, Gregory D, Wright, Maurice A, Quinn, Mary G, Fioravanti, Suzanne, Harold, Nancy, Schuler, Barbara, Thomas, Rebecca R, Grem, Jean L

“…New chemotherapy regimens for patients with colorectal cancer have improved survival, but at the cost of clinical toxicity. Oxaliplatin, an agent used in…”
Get full text

Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients by TAKIMOTO, C. H, MORRISON, G, ISMAIL, A. S, FLEMMING, D, GOSKY, D. M, HIROTA, H, BERGER, S. J, BERGER, N. A, CHEN, A. P, SHAPIRO, J. D, ARBUCK, S. G, WRIGHT, J, HAROLD, N, HAMILTON, J. M, ALLEGRA, C. J, GREM, J. L, QUINN, M, MONAHAN, B. P, BAND, R. A, COTTRELL, J, GUEMEI, A, LLORENS, V, HEHMAN, H

“…We conducted a phase I and pharmacologic study of a weekly 96-hour infusion of irinotecan to determine the maximum-tolerated dose, define the toxicity profile,…”
Get full text

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors by Wright, Maurice A, Morrison, Geraldine, Lin, Pengxin, Leonard, Gregory D, Nguyen, Dat, Guo, Xaiodu, Szabo, Eva, Hopkins, Jon L, Leguizamo, Jorge P, Harold, Nancy, Fioravanti, Suzanne, Schuler, Barbara, Monahan, Brian P, Saif, M Wasif, Quinn, Mary G, Pang, Janet, Grem, Jean L

“…Purpose: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse…”
Get full text

Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors by GREM, Jean L, HAROLD, Nancy, GROLLMAN, Frank, MORRISON, Geraldine, TAKIMOTO, Chris H, SHAPIRO, Jeremy, BI, Dao-Qin, QUINN, Mary G, ZENTKO, Suzanne, KEITH, Bruce, HAMILTON, J. Michael, MONAHAN, Brian P, DONAVAN, Sean

“…Fluorouracil (5-FU) given as a weekly, high-dose 24-hour infusion is active and tolerable. We evaluated an oral regimen of eniluracil (which inactivates…”
Get full text

Impact of Two Weekly Schedules of Oral Eniluracil Given with Fluorouracil and Leucovorin on the Duration of Dihydropyrimidine Dehydrogenase Inhibition by KEITH, Bruce, GUO, Xiao-Du, ZENTKO, Suzanne, HAROLD, Nancy, SCHULER, Barbara, QUINN, Mary, SHAPIRO, Jeremy, GREM, Jean L

“…Purpose : This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine…”
Get full text

A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients by GREM, Jean L, HAROLD, Nancy, QUINN, Mary G, MONAHAN, Brian P, KEITH, Bruce, CHEN, Alice P, KAO, Viven, TAKIMOTO, Chris H, HAMILTON, J. Michael, PANG, Janet, PACE, Marie, JASSER, Gada B

“…Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases I and II through a mechanism…”
Get full text

A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer by Karzai, Fatima H., Apolo, Andrea B., Cao, Liang, Madan, Ravi A., Adelberg, David E., Parnes, Howard, McLeod, David G., Harold, Nancy, Peer, Cody, Yu, Yunkai, Tomita, Yusuke, Lee, Min‐Jung, Lee, Sunmin, Trepel, Jane B., Gulley, James L., Figg, William D., Dahut, William L.

“…Objective TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open‐label study evaluated the safety,…”
Get full text

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer by Madan, Ravi A., Karzai, Fatima H., Ning, Yang‐Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min‐Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.

“…Objective To determine the safety and clinical efficacy of two anti‐angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. Patients…”
Get full text

A Pilot Study of Interferon α-2a, Fluorouracil, and Leucovorin Given with Granulocyte-Macrophage Colony Stimulating Factor in Advanced Gastrointestinal Adenocarcinoma by SHAPIRO, J. D, HAROLD, N, LASH, A, GROLLMAN, F, FLEMMING, D, BEHAN, K, JOHNSTON, P. G, HALLER, D, QUINN, M, MORRISON, G, GREM, J. L, TAKIMOTO, C, HAMILTON, J. M, VAUGHN, D, CHEN, A, STEINBERG, S. M, LIEWEHR, D, ALLEGRA, C, MONAHAN, B

“…We reported previously that the addition of recombinant Escherichia coli human granulocyte-macrophage colony stimulating factor (GM-CSF) to a 5-fluorouracil…”
Get full text

Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC) by Morris, John Charles, Rossi, Gabriela R., Harold, Nancy, Tennant, Lucinda, Ramsey, William Jay, Vahanian, Nicholas N., Link, Charles J.

“…Abstract only 8094 Background: Lung cancer is the leading cause of cancer-related mortality. Tumor progression after initial chemotherapy has a poor prognosis…”
Get full text

Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact by Madan, Ravi Amrit, Donahue, Renee Nicole, Singh, Harpreet, Karzai, Fatima, Theoret, Marc Robert, Heery, Christopher Ryan, Strauss, Julius, Harold, Nancy, Couvillon, Anna, Marte, Jennifer L., Hankin, Amy, Grenga, Italia, Chun, Guinevere, Cordes, Lisa M, Figg, William Douglas, Arlen, Philip M., Dahut, William L., Schlom, Jeffrey, Gulley, James L.

“…Abstract only…”
Get full text

Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR) by Couvillon, Anna, Beatson, Melony A., Harold, Nancy, Karzai, Fatima H., Madan, Ravi Amrit, Gulley, James L., Dahut, William L.

“…Abstract only 132 Background: Patients that receive docetaxel are observed closely for HSRs. Severe HSRs have been reported in patients premedicated with…”
Get full text

Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC) by Karzai, Fatima, Madan, Ravi Amrit, Ning, Yang-Min, Theoret, Marc Robert, Arlen, Philip M., Parnes, Howard L., Ojemuyiwa, Michelle A., Strauss, Julius, Dawson, Nancy Ann, McLeod, David G., Harold, Nancy, Couvillon, Anna, Cordes, Lisa M, Chen, Clara, Steinberg, Seth M., Sissung, Tristan M., Price, Douglas K., Gulley, James L., Figg, William Douglas, Dahut, William L.

“…Abstract only 272 Background: AA pts experience greater prostate cancer (PC) incidence and mortality compared to Caucasian (C) pts but are underrepresented in…”
Get full text

Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer by Madan, Ravi Amrit, Donahue, Renee Nicole, Singh, Harpreet, Karzai, Fatima, Theoret, Marc Robert, Heery, Christopher Ryan, Strauss, Julius, Harold, Nancy, Couvillon, Anna, Marte, Jennifer L., Hankin, Amy, Grenga, Italia, Chun, Guinevere, Rosner, Inger L., McLeod, David G., Cordes, Lisa M, Figg, William Douglas, Dahut, William L., Schlom, Jeffrey, Gulley, James L.

“…Abstract only 214 Background: Enzalutamide (enz) is FDA approved for advanced prostate cancer, but studies are evaluating enz in earlier stages of disease. We…”
Get full text

Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC) by Morris, John Charles, Rossi, Gabriela R., Harold, Nancy, Tennant, Lucinda, Ramsey, William Jay, Vahanian, Nicholas N., Link, Charles J.

“…Abstract only 2571 Background: Lung cancer is the leading cause of cancer-related mortality. Patients progressing after initial systemic therapy have a poor…”
Get full text

A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) by Ojemuyiwa, Michelle A., Karzai, Fatima, Shah, Avani Atul, Theoret, Marc Robert, Harold, Nancy, Chun, Guinevere, Figg, William Douglas, Apolo, Andrea Borghese, Price, Douglas K., Madan, Ravi Amrit, Gulley, James L., Dahut, William L.

“…Abstract only…”
Get full text

Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC) by Karzai, Fatima, Madan, Ravi Amrit, Theoret, Marc Robert, Arlen, Philip M., Strauss, Julius, Chun, Guinevere, Couvillon, Anna, Harold, Nancy, Chen, Clara, Dawson, Nancy Ann, Apolo, Andrea Borghese, Steinberg, Seth M., Trepel, Jane B., Wright, John Joseph, Price, Douglas K., Gulley, James L., Figg, William Douglas, Dahut, William L.

“…Abstract only…”
Get full text

A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer by Ojemuyiwa, Michelle A., Karzai, Fatima H., Shah, Avani Atul, Theoret, Marc Robert, Harold, Nancy, Chun, Guinevere, Couvillon, Anna, Apolo, Andrea Borghese, Price, Douglas K., Madan, Ravi Amrit, Figg, William Douglas, Gulley, James L., Dahut, William L.

“…Abstract only 218 Background: Trebananib is an angiopoietin1/2 antagonist peptibody. Androgens stimulate expression of VEGF via activation of hypoxia inducible…”
Get full text

Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC) by Karzai, Fatima, Madan, Ravi Amrit, Theoret, Marc Robert, Arlen, Philip M., Dawson, Nancy Ann, Rosner, Inger L., McLeod, David G., Wright, John Joseph, Cordes, Lisa M, Couvillon, Anna, Chun, Guinevere, Harold, Nancy, Steinberg, Seth M., Trepel, Jane B., Price, Douglas K., Gulley, James L., Figg, William Douglas, Dahut, William L.

“…Abstract only 235 Background: Docetaxel (D) improves overall survival in metastatic castrate-resistant prostate cancer (mCRPC), but benefits remain…”
Get full text